74
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but whether it reduces fracture risk in these women is not known.

          Related collections

          Author and article information

          Journal
          JAMA
          JAMA
          American Medical Association (AMA)
          0098-7484
          0098-7484
          Aug 18 1999
          : 282
          : 7
          Affiliations
          [1 ] Division of Research, Kaiser Permanente, Oakland, Calif 94611-5400, USA. bxe@dor.kaiser.org
          Article
          joc90496
          10.1001/jama.282.7.637
          10517716
          7ed6d210-6a10-4a1a-bf26-94cf4f5c86d3
          History

          Comments

          Comment on this article